prove worth amidst choppier
follow earn rais ep estim slightli price target
move quarter way encapsul believ
continu attract long-term hold manag beat initi
ep guidanc mid-point clear given pre-announc came
end first week march much beat march use tri
acceler improv dental cost substanti margin hit near
term strong growth busi abat ebit
growth life scienc diagnost dental theori start reap
reward turn-around effort therebi ensur rel smooth earn
stream improv growth rate industri investor re-assur
variou chang us healthcar market regul pama
appear crimp growth pll continu make good headway
return due substant cost take-out initi look like tough
deal term time take step back believ oper profit growth
despit dental declin prove standout multi-industri report
season help drive revers dhr rel under-perform
fy guid look conserv convers investor suggest fair amount
push pull reaction figur one hand wari
whether new ep guid year emb much tailwind diagnost
flu tailwind segment unlik repeat fx
consider tailwind may fade estim
hand also view lean toward fy guid
increas mid-point look fairli conserv given fx deal close
earlier month togeth could account amount dental ebit declin
evid unlik repeat organ sale growth guid
look aggress follow growth given
easier comp even account big slowdown cepheid diagnost
quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
flow oper
valuat leverag metric
year pll industri water qualiti
dental close trough flattish
think oper margin rebound
analysi suggest minim price
present contrast see higher capit
deploy year
increment margin alongsid share
repurchas proxi see path
ep inc amort impli
share price within reach
regulatori concern life scienc diagnost
market lead weaker expect organ
dental get much wors think short answer dental ebitda margin
ebit margin drop
appear undertak radic self-surgeri quarter
becam appar trend busi exceed manag
expect underli basi organ sale growth closer flat line rather
drop report effort drain inventori equip
well tradit consum natur caus substanti decrement margin
q-o-q basi due fix cost under-absorpt appear measur need
replic given reason sell-through trend see
normal flattish sale trajectori y-o-i
pll industri microelectron hold rel limit exposur
short-cycl industri end-market worri around peak growth
rate one reason stock appeal present electron one area
worri soften buoyant compani
recent confirm slowdown underway exposur via
pll industri busi microelectron seem slowdown visibl yet
compani may take market share
environment appli core margin pick one concern
multi-industri sector inflationari cost pressur re-invest need amidst
effort develop digit busi instanc may crimp increment margin
mani compani seen evid earn peer
nvent dhr segment classic industri segment
somewhat concern first glanc seem suffer weak margin
core margin declin grow despit
organ sale growth re-invest seem key reason
sinc late input cost appear culprit posit price
absorb re-invest rather cost inflat would expect therefor
core leverag overal margin trajectori pick consider
invest hike anniversari mid-year
 firepow despit acquisit earli april manag still believ
substanti balanc sheet capac estim
free cash flow increas y-o-i leav compani
confid abil quickli de-lev balanc blue sky
scenario assum leverag increas nd/ebitda level wit post pall
transact believ compani capac remain
follow acquisit could yield double-digit medium term ep accret
expect surpris weak dental headwind proactiv channel
destock surpris strength cepheid boost strong flu season
moder
believ dental trend trough
cepheid organ growth moder benefit strong flu season wane
strong core margin expans continu life scienc diagnost
despit continu invest headwind dental
dental organ sale growth yoy equipmenttradit consumablesspecialti consumablestot sale growth cepheid actual organ growth initi cepheid deal model organ growth expectationscepheid growth expect onwardstheprimari reason spread expect report growth uplift strong flu seasonop segment profit margin bridg start segment margin mix segment margin margin detailcor chang margin barclay danah corp
despit acquisit manag still believ firepow free-cash-flow
blue sky scenario assum could reach infer double-digit medium term
quickli de-lev balanc sheet follow
pall cepheid acquisit
valuat like cheap could
compani re-lev balanc sheet post-pll
level estim would avail
capit deploy toward
support manag success track record
hand pension contribut acquisitionleverag nd/ebitda avail deploy toward accret capit deploymentcapit deploy valuat multipl paid ev/ebitda corpbeckman coulter inccepheidtektronix incnobel biocar hold agflukemedium term margin expans bp total announc deal valu mn announc total valu mil medium term margin expans barclay danah corp
barclay research compani data unit multipl per share unless otherwis state
barclay research compani data unit multipl per share unless otherwis state
incom tax net current current lt lt lt liabil sharehold barclay danah corp
barclay research compani data unit multipl per share unless otherwis state
work flow cash flow flow flow cash revenu changelif ebitlif marginlif profit changelif segment barclay danah corp
barclay research compani data unit multipl per share unless otherwis state
total sciencesdiagnostics product id water qualiti dentaltotalsal profit oper oper splitbiopharma pharma industri clinic appli research diagnost lb radiomet cepheid food bev packag suppli chain industri cpg pharma muni market size posit mixequip consum consum consum consum tradit consum specialti consum consum brandsbeckman coulter life scienc sciex leica microsystem pall molecular devic phenomenexbeckman coulter leica biosystem radiomet cepheidvideojet esko x-rite pantonehach trojan chemtreat kavo kerr nobel biocar ormcodistributiondirect distribut distribut distribut distribut ge sartoriu thermofish watersabbott agil aler roch siemensdov brother industri konica minoltacalgon carbon align patterson straumanngeograph sale split distribut destinationlif splitlif profit splitanalyt physic medic major product group barclay danah corp
julian mitchel herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
